Cover Image
市場調查報告書

B型血友病:開發平台分析

Hemophilia B - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232835
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
B型血友病:開發平台分析 Hemophilia B - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 112 Pages
簡介

B型血友病是由於第IX凝血因子不足造成的遺傳性出血疾病。如果缺乏足夠的第九凝血因子,就無法凝固血液,有效地堵住出血部位。主要症狀有關節內出血,以及伴隨而來的關節痛·腫脹,紫斑,伴隨環狀切除的大量出血,消化道·尿道出血,鼻血等。主要的治療方法有補充缺箏的凝血因子等。

本報告提供全球各國治療B型血友病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

B型血友病概要

治療藥的開發

  • B型血友病開發中產品:概要
  • B型血友病開發中產品:比較分析

各企業開發中的B型血友病治療藥

大學/研究機關研究中的B型血友病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

B型血友病治療藥:開發中的產品一覽(各企業)

按B型血友病治療藥:研究中的產品一覽(大學/研究機關)

B型血友病治療藥的開發企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca Plc
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • RegenxBio Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.

B型血友病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • albutrepenonacog alfa
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ALN-AT3
  • AMT-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • CB-813d
  • B型血友病細胞療法
  • 第IX凝血因子(基因改造型)
  • 第IX凝血因子(基因改造型)
  • 第IX凝血因子FC(基因改造型), Fc 融合蛋白品質
  • 第VIIa凝血因子 (基因改造型)
  • concizumab
  • CSL-689
  • DTX-101
  • B型血友病遺傳基因療法
  • B型血友病第九凝血因子活性化用遺傳基因療法
  • B型血友病第九凝血因子活性化用遺傳基因療法
  • MOD-5014
  • MOD-9017
  • nonacog beta pegol
  • PF-06741086
  • SB-FIX
  • SPK-FIX
  • SVF-VIIa

B型血友病治療藥:開發中產品的最新趨勢

B型血友病治療藥:開發暫停的產品

B型血友病治療藥:開發中止的產品

B型血友病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8522IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 6, 6, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Hemophilia B.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia B Overview
  • Therapeutics Development
    • Pipeline Products for Hemophilia B - Overview
    • Pipeline Products for Hemophilia B - Comparative Analysis
  • Hemophilia B - Therapeutics under Development by Companies
  • Hemophilia B - Therapeutics under Investigation by Universities/Institutes
  • Hemophilia B - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hemophilia B - Products under Development by Companies
  • Hemophilia B - Products under Investigation by Universities/Institutes
  • Hemophilia B - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics B.V.
    • Bayer AG
    • Biogen Inc
    • Catalyst Biosciences, Inc.
    • China Biologic Products, Inc.
    • CSL Limited
    • Dimension Therapeutics, Inc.
    • Green Cross Corporation
    • MolMed S.p.A.
    • Novo Nordisk A/S
    • OPKO Biologics Ltd
    • Pfizer Inc.
    • Pharming Group N.V.
    • RegenxBio Inc.
    • rEVO Biologics, Inc.
    • Sangamo BioSciences, Inc.
    • Shire Plc
    • Spark Therapeutics, Inc.
    • UniQure N.V.
  • Hemophilia B - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMT-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAX-335 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1093884 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-2679d - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant), albumin fusion protein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant), pegylated - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • concizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fitusiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LR-769 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marzeptacog alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-1113A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOD-5014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06741086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-FIX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPK-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVF-VIIa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hemophilia B - Dormant Projects
  • Hemophilia B - Discontinued Products
  • Hemophilia B - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2016: Alprolix obtains reimbursement across the United Kingdom
      • Sep 07, 2016: Catalyst Biosciences to Focus on Improved Factor IX Clinical Hemostasis Program
      • Sep 06, 2016: Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing
      • Jul 26, 2016: CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress
      • Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders
      • Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress
      • Jul 19, 2016: CSL Behring to Present New Data for IDELVION at the World Federation of Hemophilia 2016 World Congress
      • Jul 18, 2016: Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data on ALPROLIX at World Federation of Hemophilia 2016 World Congress
      • Jun 06, 2016: Sobi: First Alprolix sales in the EU
      • May 24, 2016: Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst Next-Generation Factor VIIa Product CB 813d
      • May 16, 2016: Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of hemophilia B
      • May 13, 2016: Alprolix (rFIXFc) approved in the EU for the treatment of hemophilia B
      • May 12, 2016: IDELVION (rFIX-FP) - European Commission Approval
      • May 11, 2016: CSL Behring's Innovative Therapy for Hemophilia B Patients, IDELVION, Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration
      • May 11, 2016: European Commission Approves IDELVION --CSL Behring Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia B, H2 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hemophilia B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Hemophilia B - Pipeline by Amarna Therapeutics B.V., H2 2016
  • Hemophilia B - Pipeline by Bayer AG, H2 2016
  • Hemophilia B - Pipeline by Biogen Inc, H2 2016
  • Hemophilia B - Pipeline by Catalyst Biosciences, Inc., H2 2016
  • Hemophilia B - Pipeline by China Biologic Products, Inc., H2 2016
  • Hemophilia B - Pipeline by CSL Limited, H2 2016
  • Hemophilia B - Pipeline by Dimension Therapeutics, Inc., H2 2016
  • Hemophilia B - Pipeline by Green Cross Corporation, H2 2016
  • Hemophilia B - Pipeline by MolMed S.p.A., H2 2016
  • Hemophilia B - Pipeline by Novo Nordisk A/S, H2 2016
  • Hemophilia B - Pipeline by OPKO Biologics Ltd, H2 2016
  • Hemophilia B - Pipeline by Pfizer Inc., H2 2016
  • Hemophilia B - Pipeline by Pharming Group N.V., H2 2016
  • Hemophilia B - Pipeline by RegenxBio Inc., H2 2016
  • Hemophilia B - Pipeline by rEVO Biologics, Inc., H2 2016
  • Hemophilia B - Pipeline by Sangamo BioSciences, Inc., H2 2016
  • Hemophilia B - Pipeline by Shire Plc, H2 2016
  • Hemophilia B - Pipeline by Spark Therapeutics, Inc., H2 2016
  • Hemophilia B - Pipeline by UniQure N.V., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hemophilia B - Dormant Projects, H2 2016
  • Hemophilia B - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hemophilia B, H2 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top